Is Moderna Stock Too Expensive in 2022?
Moderna (NASDAQ: MRNA) stock has soared for the past two years thanks to its leadership in the coronavirus vaccine market. It's gained 1,200% over that time period. First, investors bet on the company's ability to bring a vaccine to market. Then, they doubled down on their positions when Moderna commercialized its product and started to generate billions of dollars in revenue and profit.
But over the past few months, some investors started to question the idea of buying Moderna stock at this point. After all, nearly 63% of the U.S. population has been fully vaccinated. And experts -- even leaders at Moderna -- have said the pandemic may ease into an endemic situation as early as this year. Considering this point, is Moderna stock too expensive?
Image source: Getty Images.
Source Fool.com
